Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of GDC-0199 (ABT-199) With Bendamustine and Rituximab Versus Bendamustine/Rituximab or GDC-0199/Rituximab in Relapsed/Refractory Follicular Lymphoma
2014-000576-26Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax in follicular lymphoma (FL) (3 arms), sponsored by AbbVie Inc. Primary endpoint: PET-defined complete response rate. Started Jun 2014; status: completed.
02
Drugs
venetoclax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2014-000576-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000576-26.